Results: Sixty three cases of newly diagnosed patients with hematological malignancies were investigated prior to treatment. By using leishman's stain, hematoxyline and Eosin stains and selected cytochemical stains, the included cases were diagnosed morphologically as lymphoid malignancies (acute and chronic), myeloid malignancies (acute type) and a group of undifferentiated hematological malignancies. Based on the pattern of reactivity to a panel of lineage associated antibodies (CD markers) the hematological malignancies were classified into two major types; lymphoid (precursor and mature type) and myeloid (acute myeloid type) with further sub classification. Conclusions: The diagnosis of the hematological malignancies is mainly based on morphology, but diagnostic yield is highly increased by the use of the immunophenotyping analysis.
The diagnosis of the hematological malignancies is not complete unless morphological examination is supplemented by further studies like immunophenotyping, karyotyping (conventional cytogenetic) and/or molecular studies.
[12]
H Morphology remains to be important and is the key front-line diagnostic technique which must not be ignored, in addition it is the foundation upon which decision about further scientific assessment are based.
[13] The standard sequence to morphological review is peripheral blood film, bone marrow aspiration smear and biopsy. [14] Laboratory diagnosis in patients with a hematological malignancies has three major applications: establishing the diagnosis, prognostic classification and evaluation of treatment effectiveness. Immunophenotypic evaluation is currently recognized to provide essential information for all three applications. [15] Immunophenotyping utilizes the use of primary antibodies that are targeted against certain antigens in the cell. The primary antibodies can be divided into two categories polyclonal and monoclonal antibodies.
[16]
Antigens may be expressed on the surface of the cells within the cytoplasm or within the nucleus. Many monoclonal antibodies react with lymphoid or myeloid antigens have been characterized and are described by cluster of differentiation (CD) numbers. The CD number refers to a group of antibodies that recognize the same antigen and also refers to the antigen expressed.
[17] Immunophenotyping has become the essential method for proper classification of hematopoietic neoplasms, a wide range of monoclonal antibodies are available to recognize various hematopoietic cells based on their surface and cytoplasmic antigens. Leukemia and lymphoma cells usually cannot be detected with a single immunological marker so the use of a monoclonal antibodies panel consisting of multiple antibodies is required for supporting the provisional diagnosis.
[18] and/or biopsies of all cases were subjected for immunostaining for both myeloid and lymphoid markers to confirm the myeloid or lymphoid nature of the disease. Immunostaining was performed on the peripheral blood smears when bone marrow aspirate is dry or diluted, like in some cases of hairy cell leukemia, and also in cases of leukemias with good number of leukemic cells in the peripheral blood. Fresh blood and bone marrow aspirate with or without bone marrow biopsy were taken from cases of hematological malignancies prior to the initiation of treatment. Peripheral blood sample (2.5 ml) was withdrawn, 2 ml were transferred to Ethylene diaminetetra-acetic acid (EDTA) tube for complete blood counts, while 0.5 ml was used directly to prepare smears for routine hematology staining (Leishman's stain) and immunocytochemical staining. Bone marrow aspirate (0.5 ml) was directly used for preparation of marrow smears for Leishman's stain, cytochemical stains and immuocytochemical stains. Bone marrow biopsy was taken and sent for processing in the histopathology laboratory. For patients with lymph node biopsy, the histopathological slides were reviewed and the paraffin blocks were used to prepare slides for immunostaining. All samples for immunocytochemistry (ICC) staining were fixed with absolute methanol and all the tissues for immunohistochemistry (IHC) staining were fixed by formalin and then paraffin embedded (FFPE). All samples were stained according to Leica microsystems staining protocol (NovoLink Polymer detection system 250 tests, product No: RE7140-K,Wetzlar, Germany); with some modification. Twelve monoclonal antibodies (CD3, CD5, CD10, CD19, CD20, CD33, CD34, Kappa, Lambda and anti-Myeloperoxidase (anti-MPO) from Leica microsystems, Wetzlar, Germany; and CD45 and Bcl2 from Dako A/S, DK-2600 Glostrup, and Denmark) were used for immunostaining. In the present study, only ten cases, who are suitable for flowcytometric immunophenotyping (fresh and good sample size with good percentage of pathological cells) were referred for flowcytometry immunophenotypic analysis (BD Accuri™ C6 FlowCytometer, from BD Biosciences, USA) in a private laboratory to confirm the results of immunocytochemistry and immunohistochemistry. An informed consent was obtained from patient and / or one of parents before enrollment in the study. The work was approved by the Ethical committee of Basrah Medical College. Figure-1 , explains how we dealt with different cases and how we used our panel of antibodies to reach the diagnosis. We followed a scheme that is similar to the WHO classification system of HMs in which we first tried to identify whether the case is myeloid, B-lymphoid or Tlymphoid. 
PATIENTS AND METHODS

RESULTS
The age and sex distribution of cases are shown in (Table-1 
Fig 3. Morphological classification of HMs
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-ve (2) +ve (2) Mixed(lymphoid/ myeloid) N=1 -ve (1) +ve (1) +ve (1) +ve (1) +ve (1) -ve (1) +ve ( M5. The majority of cases were M4 (33.33%) and M5 (26.67%) followed by M2 (20%) while M1 and M3 represents (6.67%) and (13.33%) respectively. During the period of the study, no cases of M0, M6 and M7 were diagnosed. The panel of available monoclonal antibodies were used to recognize and subtype cases that were diagnosed as undifferentiated HMs by morphology and cytochemistry (six cases). By immunophenotyping two cases were found to be precursor B lymphoid malignancy (B-ALL) and one was assigned as acute myeloid leukemia. One case showed positive immunostaining for both B-lymphoid markers and one myeloid marker (CD33), this could be B-ALL with aberrant expression of myeloid marker or bilineage/biphenotypic leukemia. Two cases remained undifferentiated despite the use of immunological methods and were regarded as undifferentiated (Uddx), Figure ( 
DISCUSSION
The cases of Hematological malignancies included in this study were divided into seven age groups. As with most other cancers, the possibility of being diagnosed with HMs increases markedly with age. However, HMs can be diagnosed at any age, with different subtypes predominating at different ages.
[22]
. In the present study the highest frequency of patients with HMs was recorded in the age group 41-50 years and more than 60 years (19.05% each). Cases among the age group below 10 years constitute 7.94% of all cases of HM, and are of acute leukemias, mostly of lymphoid type. These results are in agreement with Mckenzie SB and what was reported about the peak incidence of acute leukemias in the first decade and that chronic leukemias are rare in children.
[23] The percentage of males was higher than females in all types of HMs (65.07% compared to 34.92%) in this study. This finding is in agreement with Sant, et al who found that HMs incidence in Europe was generally lower in women than men; this is a well-known phenomenon and could be in part the result of lower exposure to environmental and occupational risk factors. The malignant precursor lymphoid cells (lymphoblasts) show aberrant marker expression and deviation from the normal arrangement of maturation that can help to differentiate them from normal progenitor cells depending on the pattern of expression of these markers.
[24] The lineage assignment and the level of differentiation was determined by the presence of the pan-lineage markers e.g. CD19 and CD20 for B-cell lineage and CD3 for the T-cell lineage. Accordingly the lymphoid malignancies are diagnosed as precursor (Acute) B-cell and T-cell lymphoid malignancies. In correlation to the morphological classification, the cases diagnosed morphologically as acute lymphoid type of hematological malignancies without determination of the cell lineage. The use of monoclonal antibodies as a diagnostic aid in acute myeloid leukemia (AML) has improved the diagnosis of cases in which the definitive diagnosis can't be reached by using morphological and cytochemical stains alone. In the current study, immunological markers are used to identify acute myeloid leukemia (AML) and distinguish it from acute lymphoblastic leukemia (ALL) including reactivity with antibodies CD33 and anti-myeloperoxidase (anti-MPO). These markers show little difference between AML subtypes. So for more precise sub classification of AML, monoclonal antibodies that show some selectivity for immature cells, mature cells, granulocytic, monocytic, erythroid and megakaryocytic differentiation should be available. However, it was possible to make differentiation between the subtypes of AML using the CD33 and anti-MPO in correlation with morphology and cytochemical stains in study group. Of the 63 cases included in the study, 6 (9.52%) cases are classified morphologically as undifferentiated hematological malignancies, in which blast cells are determined morphologically and are further analyzed by immunophenotyping. The immunological analysis results in establishing the diagnosis of four cases; acute myeloid leukemia, B-cell type acute lymphoblastic leukemia, common B-ALL and one case shows positive immunostaining for both lymphoid (Bcell markers) and myeloid marker (CD33). This case could be either B-ALL with aberrant expression of myeloid marker (CD33) or bilineage / biphenotypic leukemia. Biphenotypic leukemia should not be diagnosed on the basis of the expression of a single in appropriate marker. A scoring system is usually followed in such cases. In this system, proposed by the WHO classification of hematological malignancies, the reactivity to several antibodies should be considered with points being counted according to the specificity of that antibody.
[25] Unfortunately this system
could not be applied in this study because of the unavailability of some of these markers (TdT, CD13, CD79a, CD22, IgM, anti-TCR, CD2, CD8, CD117, CD65, CD24, CD7, CD1a, CD14, CD15 and CD64). So the immunological analysis results in reduction of the undifferentiated hematological malignancies from six to two cases. These two cases remain undifferentiated and are classified as acute undifferentiated leukemia. However, markers for rare leukemias, e.g. acute megakaryoblastic leukemia or M7, were not available, and hence these rare entities cannot be excluded with certainty depending on morphological assessment alone. From this study it can be concluded that although the diagnosis of hematological malignancies is mainly based on morphology, but the diagnostic yield is highly increased by the use of the immunological methods. Leukemia and lymphoma cells cannot, usually, be detected with a single immunological marker. Instead, the use of monoclonal antibodies panels consisting of multiple antibodies is required for supporting the provisional diagnosis based on morphological findings.
